

Figure S1. Validation of GGC repeat expansion and intranuclear inclusions in NIID-affected individuals. (A-B) Representative electropherogram of the RP-PCR assay (left) and the GC-PCR assay (right) revealed abnormal expanded repeats in NIID-affected case subjects (A), and normal repeats in control subjects (B). (C-D) Representative skin biopsy sample showed positive p62-staining (C) and ubiquitin-staining (D) intranuclear inclusions (arrows) in most NIID-affected case subjects. Scale bars, 10 μ m.(E) Representative electron microscopy imaging displayed intranuclear inclusions (arrow). Scale bars, 1 μ m.




Table S1. Initial manifestations in different clinical phenotypes of NIID.

Initial symptoms	Total	Clinical Phenotype			
		Dementia-dominant type (n=94)	Movement disorder -dominant type (n=63)	Muscle weakness-dominant type (n=29)	Paroxysmal symptom-dominant type (n=61)
Muscle weakness	10.1%	0.0%	0.0%	86.2%	0.0%
Cognitive impairment	23.1%	60.6%	0.0%	0.0%	0.0%
Movement disorders	22.3%	0.0%	87.3%	0.0%	0.0%
Paroxysmal symptoms	32.8%	25.5%	4.8%	6.9%	85.2%
Autonomic dysfunctions	11.7%	13.8%	7.9%	6.9%	14.8%

Table S2. Neurophysiological examination of the muscle weakness-dominant phenotype.

Case	Sex	Age at evaluation	Ulnar motor		Median motor		Tibial motor		Peroneal motor		Ulnar sensory		Median sensory		Sural sensory		Needle EMG/ report
			Amp, mV (>7)	CV, m/s (>50)	Amp, mV (>7)	CV, m/s (>50)	Amp, mV (>7)	CV, m/s (>40)	Amp, mV (>3)	CV, m/s (>40)	Amp, μ V (>7)	CV, m/s (>45)	Amp, μ V (>7)	CV, m/s (>45)	Amp, μ V (M>8; F>6)	CV, m/s (>40)	
M-1	M	69	13.0	37.8	11.9	40.7	8.0	31.2	4.5	34.8	NR	NR	5.4	37.2	7.9	34.7	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-2	F	65	4.4	46.2	3.0	44.4	1.8	36.5	1.1	38.6	ND	ND	12.6	37.0	1.4	39.8	ND/ Sensorimotor neuropathy with axonal damage predominant
M-3	M	70	7.3	36.1	7.2	40.5	NR	NR	NR	NR	11.6	38.0	10.1	48.9	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-4	M	51	12.1	48.2	11.4	52.9	9.5	35.1	NR	NR	8.3	49.6	10.7	51.1	12.2	42.6	Neurogenic damage/ Mixed demyelinating and axonal motor neuropathy
M-5	M	61	1.3	42.5	0.6	26.4	4.0	29.4	NR	NR	NR	NR	5.2	41.3	6.2	34.6	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-7	M	54	9.5	45.4	4.9	51.6	9.5	33.7	0.9	37.2	NR	NR	3.7	49.1	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-11	M	22	5.3	36.7	4.0	36.3	2.4	29.0	1.4	28.3	10.0	41.4	9.4	34.1	4.3	32.3	Neurogenic damage/ Sensorimotor neuropathy with axonal damage predominant
M-12	M	23	12.8	46.2	17.3	47.5	15.6	38.7	8.7	39.0	16.0	55.6	44.3	61.9	27.1	57.0	Neurogenic damage/ Mixed demyelinating and axonal motor neuropathy
M-13	M	32	7.3	47.2	14.2	47.7	2.4	39.4	1.5	34.2	4.6	47.4	6.2	54.5	3.5	40.7	Neurogenic damage/ Sensorimotor neuropathy with axonal damage predominant
M-15	M	34	15.6	45.6	18.3	46.1	15.3	34.7	14.1	36.2	6.8	41.4	12.5	48.3	9.3	37.5	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-16	F	48	5.3	50.0	6.0	50.0	NR	NR	NR	NR	6.4	42.3	5.7	43.3	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-18	M	43	6.4	46.8	3.4	44.6	1.8	39.6	6.8	39.5	9.6	53.6	11.6	55.7	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-19	M	41	3.4	41.8	10.4	41.1	NR	NR	1.3	36.3	9.3	59.7	0.2	39.2	2.1	40.1	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-20	M	47	9.1	36.1	7.1	41.1	1.0	28.2	NR	NR	2.8	35.5	3.5	43.8	7.9	32.3	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy

M-21	M	49	8.7	37.8	8.7	38.1	NR	NR	0.2	21.0	7.3	36.2	15.1	37.4	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-22	M	48	9.7	50.0	7.1	39.7	NR	NR	1.4	34.7	3.3	39.4	7.1	34.9	1.9	35.4	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy
M-25	M	72	13.1	60.2	12.2	60.8	21.1	43.2	5.5	41.0	7.5	50.0	11.0	51.2	8.7	53.3	Neurogenic damage/ Pure axonal motor neuropathy
M-26	M	53	4.0	35.9	0.3	23.1	1.0	27.2	NR	NR	3.7	29.7	7.3	31.9	NR	NR	Neurogenic damage/ Mixed demyelinating and axonal sensorimotor neuropathy

Amp=amplitude; CV=conduction velocity; F=female; M=male; ND=not done; NR=not response.

Table S3. Spearman's rho coefficients for correlations between GGC repeat sizes and clinical symptoms. * $P < 0.05$ were considered as being statistically significant.

	GGC repeat sizes
Cognitive impairment	-0.072 ($p=0.318$)
Abnormal behavior	-0.037 ($p=0.612$)
Muscle weakness	0.142* ($p<0.05$)
Bulbar paralysis	0.156* ($p<0.05$)
Limb weakness	0.132 ($p=0.067$)
Sensory disturbance	0.044 ($p=0.543$)
Movement disorders	-0.047 ($p=0.518$)
Tremor	0.006 ($p=0.934$)
Rigidity	-0.172* ($p<0.05$)
Bradykinesia	-0.115 ($p=0.109$)
Ataxia	0.003 ($p=0.966$)
Paroxysmal symptom	-0.160* ($p<0.05$)
Disturbance of consciousness	-0.191* ($p<0.05$)
Encephalitic episodes	-0.133 ($p=0.064$)
Stroke-like episodes	-0.132 ($p=0.067$)
Generalized convulsions	-0.081 ($p=0.259$)
Chronic headache	-0.022 ($p=0.757$)
Autonomic dysfunction	-0.041 ($p=0.567$)
Bladder dysfunction	-0.081 ($p=0.263$)
Miosis	-0.082 ($p=0.258$)
Orthostatic hypotension	0.008 ($p=0.917$)
Emesis	-0.006 ($p=0.929$)
Visual loss	-0.027 ($p=0.709$)

Table S4. Comparison analysis of GGC repeat sizes between patients with different initial symptoms. *P < 0.05 were considered as being statistically significant.

	Muscle weakness	Cognitive impairment	Movement disorders	Paroxysmal symptoms	Autonomic dysfunctions	<i>p</i>
GGC repeat sizes,	143	117	124	120	122	0.226
median (IQR)	(106.00-235.00)	(103.00-135.00)	(100.50-142.00)	(104.00-138.75)	(102.00-189.00)	

Table S5. Spearman's rho coefficients for correlations between GGC repeat sizes and age at onset, scores of MMSE, MoCA, FAB, and NPI. *P < 0.05 were considered as being statistically significant.

	Age at onset	MMSE	MoCA	FAB	NPI
GGC repeat sizes	-0.196* (<i>p</i> <0.05)	0.004 (<i>p</i> =0.960)	0.013 (<i>p</i> =0.900)	0.010 (<i>p</i> =0.930)	0.059 (<i>p</i> =0.546)